Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis

被引:52
作者
Sloan, FA [1 ]
WhettenGoldstein, K [1 ]
Wilson, A [1 ]
机构
[1] DUKE UNIV,DEPT ECON,DURHAM,NC 27708
关键词
cost-effectiveness; hospital pharmacies; cost containment;
D O I
10.1016/S0277-9536(96)00393-0
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The key hypothesis of the study was that hospital pharmacies under the pressure of managed care would be more likely to adopt process innovations to assure less costly and more cost-effective provision of care. We conducted a survey of 103 hospitals and analyzed secondary data on cost and staffing. Compared to the size of the reduction in length of stay, changes in the way that a day of care is delivered appear to be minor, even in areas with substantial managed care share. The vast majority of hospitals surveyed had implemented some form of therapeutic interchange and generic substitution. Most hospitals used some drug utilization guidelines, but as of mid 1995 these were not yet important management tools for hospital pharmacies. To our knowledge, ours was the first survey to investigate the link between hospital formularies and use of cost-effectiveness analysis. At most cost-effectiveness was a minor tool in pharmaceutical decision making in hospitals at present. We could determine no differences in use of such analyses by managed care market share in the hospital's market share. One impediment to the use of cost-effectiveness studies was the lack of timeliness of studies. Other stated reasons for not using cost-effectiveness analysis more often were: lack of information on hospitalized patients and hence on the potential cost offsets accruing to the hospital: lack of independent sponsorship, and inadequate expertise in economic evaluation. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:523 / 533
页数:11
相关论文
共 28 条
[1]  
Achusim L E, 1992, Pharmacoeconomics, V2, P347
[2]  
*AM SOC HOSP PHARM, 1992, AM J HOSP PHARM, V49, P155
[3]  
[Anonymous], 1996, NURSING STAFF HOSP N
[4]   CONTROVERSIES IN ANTIMICROBIAL THERAPY - FORMULARY DECISIONS ON 3RD-GENERATION CEPHALOSPORINS [J].
BARRIERE, SL .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1986, 43 (03) :625-629
[5]  
BASTEAN B, 1995, COMMUNICATION 1120
[7]   THERAPEUTIC INTERCHANGE OF CEFAZOLIN WITH METRONIDAZOLE FOR CEFOXITIN [J].
BROWN, GR ;
CLARKE, AM .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1992, 49 (08) :1946-1950
[8]  
CRANE VS, 1993, HOSP FORMUL, V28, P859
[9]   ECONOMIC-EVALUATION OF STANDARD HEPARIN AND ENOXAPARIN FOR PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS IN ELECTIVE HIP-SURGERY [J].
DRUMMOND, M ;
ARISTIDES, M ;
DAVIES, L ;
FORBES, C .
BRITISH JOURNAL OF SURGERY, 1994, 81 (12) :1742-1746
[10]   THE AMERICAN HEALTH-CARE SYSTEM - MANAGED CARE [J].
IGLEHART, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (10) :742-747